Boston Scientific Invests $1.5B for Stake in MiRus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: seekingalpha
- Investment Scale: Boston Scientific (BSX) announced a $1.5 billion investment to acquire approximately 34% of MiRus, which focuses on biomaterials, implants, and treatment technologies for cardiovascular and orthopedic conditions, indicating the company's strategic expansion in the medical technology sector.
- Future Acquisition Option: As part of the deal, Boston Scientific received an exclusive option to fully acquire MiRus' TAVR business for an additional $3 billion in cash if MiRus meets specific clinical and regulatory milestones, providing potential growth leverage for the company.
- Technological Innovation: MiRus' SIEGEL balloon-expandable transcatheter aortic valve replacement (TAVR) system is built on a proprietary rhenium alloy and is the first nickel-free TAVR valve designed to restore function and normal blood flow in severely narrowed aortic valves, showcasing significant clinical application potential.
- Clinical Trial Progress: MiRus recently initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in high-risk surgical patients, involving up to 1,025 patients, which will support Boston Scientific's market position in cardiac treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.550
Low
94.00
Averages
108.14
High
132.00
Current: 53.550
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Invests $1.5B for Stake in MiRus
- Investment Scale: Boston Scientific (BSX) announced a $1.5 billion investment to acquire approximately 34% of MiRus, which focuses on biomaterials, implants, and treatment technologies for cardiovascular and orthopedic conditions, indicating the company's strategic expansion in the medical technology sector.
- Future Acquisition Option: As part of the deal, Boston Scientific received an exclusive option to fully acquire MiRus' TAVR business for an additional $3 billion in cash if MiRus meets specific clinical and regulatory milestones, providing potential growth leverage for the company.
- Technological Innovation: MiRus' SIEGEL balloon-expandable transcatheter aortic valve replacement (TAVR) system is built on a proprietary rhenium alloy and is the first nickel-free TAVR valve designed to restore function and normal blood flow in severely narrowed aortic valves, showcasing significant clinical application potential.
- Clinical Trial Progress: MiRus recently initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in high-risk surgical patients, involving up to 1,025 patients, which will support Boston Scientific's market position in cardiac treatment.
See More
Boston Scientific Announces $2 Billion Accelerated Share Repurchase
- Share Repurchase Plan: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan, part of its previously announced $5 billion repurchase authorization, reflecting the company's confidence in its stock value.
- Estimated Shares: Based on the closing price of $52.68 on May 15, 2026, approximately 30.4 million shares are expected to be repurchased, which will enhance the company's capital structure and improve earnings per share.
- Financial Impact: The accelerated repurchase is expected to positively impact adjusted earnings per share by $0.02 in 2026, further solidifying the company's guidance issued on April 22, 2026.
- Remaining Repurchase Capacity: After completing this repurchase, Boston Scientific will have $3 billion remaining under its repurchase authorization, providing flexibility for future capital management and shareholder returns.
See More
Boston Scientific Announces $2 Billion Accelerated Share Repurchase
- Share Repurchase Agreement: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan, part of its previously announced $5 billion share repurchase authorization, reflecting the company's confidence in its stock value.
- Estimated Shares: Based on the closing price of $52.68 on May 15, 2026, approximately 30.4 million shares are expected to be repurchased, which will significantly reduce the number of shares in circulation and potentially enhance earnings per share.
- Financial Impact: The repurchase is expected to positively impact adjusted earnings per share by $0.02 in 2026, further enhancing the company's attractiveness to investors and potentially driving up the stock price.
- Remaining Repurchase Capacity: After completing this repurchase, Boston Scientific will have $3 billion remaining under its share repurchase authorization, indicating the company's flexibility and plans for further buybacks in the future.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus and TAVR Option
- Major Investment: Boston Scientific announced a $1.5 billion investment to acquire approximately 34% equity in MiRus LLC, aimed at enhancing its portfolio for treating cardiovascular and orthopedic diseases, particularly the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's TAVR business for $3 billion upon achieving specific clinical and regulatory milestones, highlighting the company's commitment to innovative medical technologies.
- Technological Advantages: The SIEGEL valve features a unique rhenium alloy design with radial strength superior to cobalt and titanium, and its nickel-free construction and precise placement capabilities may provide physicians with advanced treatment options, potentially improving patient outcomes.
- Clinical Trial Initiation: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, which is expected to offer a less invasive treatment option for heart disease patients and further enhance market acceptance.
See More
Market Analysis: Stock Performance and Investment Recommendations
- Competitive Pressure Analysis: Boston Scientific's stock has declined due to increased competition, yet analysts suggest holding the stock, indicating confidence in its future potential and reflecting market interest in the medical device sector.
- Cloud and Defense Opportunities: Nokia is seen as a dual beneficiary in cloud computing and defense, with analysts recommending its stock, highlighting its strong performance in technology and defense contracts, which may drive future growth.
- Retail Sector Challenges: Chewy faces challenges in the retail sector, with analysts unable to recommend buying due to the impact of war, reflecting a cautious market attitude towards high-growth retail companies.
- Infrastructure Investment Outlook: Caterpillar is viewed as a beneficiary of growing infrastructure and energy demands, with analysts recommending its stock, demonstrating confidence in its strong demand in construction and energy sectors.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Invests $1.5B for Stake in MiRus
- Investment Scale: Boston Scientific (BSX) announced a $1.5 billion investment to acquire approximately 34% of MiRus, which focuses on biomaterials, implants, and treatment technologies for cardiovascular and orthopedic conditions, indicating the company's strategic expansion in the medical technology sector.
- Future Acquisition Option: As part of the deal, Boston Scientific received an exclusive option to fully acquire MiRus' TAVR business for an additional $3 billion in cash if MiRus meets specific clinical and regulatory milestones, providing potential growth leverage for the company.
- Technological Innovation: MiRus' SIEGEL balloon-expandable transcatheter aortic valve replacement (TAVR) system is built on a proprietary rhenium alloy and is the first nickel-free TAVR valve designed to restore function and normal blood flow in severely narrowed aortic valves, showcasing significant clinical application potential.
- Clinical Trial Progress: MiRus recently initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in high-risk surgical patients, involving up to 1,025 patients, which will support Boston Scientific's market position in cardiac treatment.
See More
Boston Scientific Announces $2 Billion Accelerated Share Repurchase
- Share Repurchase Plan: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan, part of its previously announced $5 billion repurchase authorization, reflecting the company's confidence in its stock value.
- Estimated Shares: Based on the closing price of $52.68 on May 15, 2026, approximately 30.4 million shares are expected to be repurchased, which will enhance the company's capital structure and improve earnings per share.
- Financial Impact: The accelerated repurchase is expected to positively impact adjusted earnings per share by $0.02 in 2026, further solidifying the company's guidance issued on April 22, 2026.
- Remaining Repurchase Capacity: After completing this repurchase, Boston Scientific will have $3 billion remaining under its repurchase authorization, providing flexibility for future capital management and shareholder returns.
See More
Boston Scientific Announces $2 Billion Accelerated Share Repurchase
- Share Repurchase Agreement: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan, part of its previously announced $5 billion share repurchase authorization, reflecting the company's confidence in its stock value.
- Estimated Shares: Based on the closing price of $52.68 on May 15, 2026, approximately 30.4 million shares are expected to be repurchased, which will significantly reduce the number of shares in circulation and potentially enhance earnings per share.
- Financial Impact: The repurchase is expected to positively impact adjusted earnings per share by $0.02 in 2026, further enhancing the company's attractiveness to investors and potentially driving up the stock price.
- Remaining Repurchase Capacity: After completing this repurchase, Boston Scientific will have $3 billion remaining under its share repurchase authorization, indicating the company's flexibility and plans for further buybacks in the future.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus and TAVR Option
- Major Investment: Boston Scientific announced a $1.5 billion investment to acquire approximately 34% equity in MiRus LLC, aimed at enhancing its portfolio for treating cardiovascular and orthopedic diseases, particularly the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's TAVR business for $3 billion upon achieving specific clinical and regulatory milestones, highlighting the company's commitment to innovative medical technologies.
- Technological Advantages: The SIEGEL valve features a unique rhenium alloy design with radial strength superior to cobalt and titanium, and its nickel-free construction and precise placement capabilities may provide physicians with advanced treatment options, potentially improving patient outcomes.
- Clinical Trial Initiation: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, which is expected to offer a less invasive treatment option for heart disease patients and further enhance market acceptance.
See More
Market Analysis: Stock Performance and Investment Recommendations
- Competitive Pressure Analysis: Boston Scientific's stock has declined due to increased competition, yet analysts suggest holding the stock, indicating confidence in its future potential and reflecting market interest in the medical device sector.
- Cloud and Defense Opportunities: Nokia is seen as a dual beneficiary in cloud computing and defense, with analysts recommending its stock, highlighting its strong performance in technology and defense contracts, which may drive future growth.
- Retail Sector Challenges: Chewy faces challenges in the retail sector, with analysts unable to recommend buying due to the impact of war, reflecting a cautious market attitude towards high-growth retail companies.
- Infrastructure Investment Outlook: Caterpillar is viewed as a beneficiary of growing infrastructure and energy demands, with analysts recommending its stock, demonstrating confidence in its strong demand in construction and energy sectors.
See More
